<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701428</url>
  </required_header>
  <id_info>
    <org_study_id>VGSKAS-12916</org_study_id>
    <secondary_id>FoU Sweden, nr 8751</secondary_id>
    <nct_id>NCT00701428</nct_id>
  </id_info>
  <brief_title>Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment</brief_title>
  <acronym>LosartanPAP</acronym>
  <official_title>Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skaraborg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Skaraborg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is a highly prevalent condition in hypertensive patients. The&#xD;
      renin-angiotension-aldosterone-system (RAAS) has a central role in blood pressure control. An&#xD;
      angiotensin-II-antagonist, Losartan, is an effective antihypertensive drug. However, some&#xD;
      patients respond to this drug worse than the others, and it is a clinical praxis to either&#xD;
      increase the dosage and/or add another drug. There is limited data regarding the impact of&#xD;
      antihypertensive drugs in OSA patients, i.e., whether or not OSA may constitute the subgroup&#xD;
      of therapy-resistent hypertensive patients. In the literature, there is no data, either,&#xD;
      whether or not CPAP treatment may have an additive blood pressure lowering impact in this&#xD;
      certain subgroup.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OSA is a highly prevalent condition in hypertensive patients and the prevalence is even&#xD;
      higher in patients with drug-resistant hypertension. The&#xD;
      renin-angiotension-aldosterone-system (RAAS) has a central role in blood pressure control. An&#xD;
      angiotensin-II-antagonist, Losartan, has an effective antihypertensive drug. However, some&#xD;
      patients respond to this drug worse than the others, and it is a clinical praxis to either&#xD;
      increase the dosage and/or add another drug. There is limited data regarding the impact of&#xD;
      antihypertensive drugs in OSA patients, i.e., whether or not OSA may constitute the subgroup&#xD;
      of therapy-resistent hypertensive patients. In the literature, there is no data, either,&#xD;
      whether or not CPAP treatment may have an additive blood pressure lowering impact in this&#xD;
      certain subgroup. The investigators will include 90 otherwise healthy, untreated hypertensive&#xD;
      men and women(age 50-69 yrs, Body-Mass-Index &lt;35 kg/m2; 60 patients with OSA, 30 non-OSA) as&#xD;
      described above. Before start of treatment, fasting blood samples will be drawn regarding the&#xD;
      neuroendocrine hormones (adrenaline, noradrenaline, plasma renin activity, angiotensin&#xD;
      II,aldosterone, pro-BNP) and cardiovascular biomarkers (CRP,interleukines, cytokines). All&#xD;
      subjects will start with Losartan 50 mg and 24 h- blood-pressure response and blood sample&#xD;
      analysis will be compared between OSA and non-OSA subjects after 6 weeks of treatment. In the&#xD;
      second 6-week period, all subjects will continue with Losartan while the half of the OSA&#xD;
      group (n=30) will be randomized to CPAP and the other 30 patients will continue with Losartan&#xD;
      only.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 h blood pressure (mean blood pressure; mmHg)</measure>
    <time_frame>Changes from Baseline in 24 h BP at 6 and 12 weeks, respectively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of sympathetic activity, RAAS-activity, cardiovascular biomarkers</measure>
    <time_frame>Changes from Baseline in Biomarkers at 6 and 12 weeks, respectively</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hypertension</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypertensive Men and Women Without OSA on Losartan (n=30)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypertensive Men and Women With OSA on Losartan (n=30)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertensive Men and Women with OSA on Losartan and CPAP (n=30)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan 50 mg daily during 6 + 6 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>CPAP during the second 6 week-period</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Auto-CPAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index &lt;35 kg/m2&#xD;
&#xD;
          -  Systolic Blood Pressure &gt;=140 mmHg and/or Diastolic Blood Pressure &gt;=95 mmHg&#xD;
&#xD;
          -  No known clinical disease except hypertension&#xD;
&#xD;
          -  No cardiovascular medication&#xD;
&#xD;
          -  Apnea-Hypopnea Index &lt; 5/h (no OSA), or Apnea Hypopnea Index &gt;=15/h (OSA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Manifest diabetes, liver- or kidney disease Signs of atrial fibrillation or former&#xD;
             myocardial infarction at electrocardiogram&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuksel Peker, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Thunström, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Gothenburg, Sahlgrenska Academy</name>
      <address>
        <city>Gothenburg</city>
        <state>West Gotaland</state>
        <zip>SE 41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Thunström E, Manhem K, Rosengren A, Peker Y. Blood Pressure Response to Losartan and Continuous Positive Airway Pressure in Hypertension and Obstructive Sleep Apnea. Am J Respir Crit Care Med. 2016 Feb 1;193(3):310-20. doi: 10.1164/rccm.201505-0998OC.</citation>
    <PMID>26414380</PMID>
  </results_reference>
  <results_reference>
    <citation>Thunström E, Manhem K, Yucel-Lindberg T, Rosengren A, Lindberg C, Peker Y. Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial. Ann Am Thorac Soc. 2016 Nov;13(11):2002-2011.</citation>
    <PMID>27548072</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skaraborg Hospital</investigator_affiliation>
    <investigator_full_name>Yuksel Peker</investigator_full_name>
    <investigator_title>MD, PhD, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Sleep Apnea</keyword>
  <keyword>Angiotensin II antagonist</keyword>
  <keyword>CPAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

